Pain Research & Management最新文献

Background: The objective of this study was to systematically evaluate the safety and efficacy of local anesthesia, general anesthesia, and epidural anesthesia in percutaneous endoscopic lumbar discectomy (PELD). Methods: We searched PubMed, EMBASE, and OVID databases for all relevant studies. All statistical analysis was performed using STATA 17.0. Results: Fourteen studies were finally included, comprising 7 randomized controlled trials and 7 retrospective studies. The total number of subjects across these studies was 1655, with 316 undergoing general anesthesia, 789 undergoing local anesthesia, and 550 undergoing epidural anesthesia. The meta-analysis of pairwise comparisons suggests that there are no differences among epidural, general anesthesia, and local anesthesia in terms of postoperative VAS, ODI, and surgery time. Regarding complications, general anesthesia has a higher complication rate compared with local anesthesia, but there are no differences between epidural and general anesthesia or between epidural and local anesthesia. In terms of anesthesia satisfaction, both general and epidural anesthesia have higher satisfaction rates compared with local anesthesia, with no significant difference between general and epidural anesthesia. The ranking of the best probabilities shows that epidural anesthesia has the lowest postoperative VAS and highest anesthesia satisfaction. General anesthesia has the lowest ODI scores. Local anesthesia has the fewest complications and operative time. Conclusion: Local anesthesia, general anesthesia, and epidural anesthesia are all safe and effective methods for PELD. Local anesthesia has advantages in complications and operation time. Epidural anesthesia is most advantageous in anesthesia satisfaction and postoperative VAS scores. General anesthesia is most advantageous in postoperative ODI. In the future, more multicenter RCTs are needed to further compare the safety and effectiveness of different anesthesia methods in PELD.

Background: Strong associations have been demonstrated between chronic musculoskeletal pain, pain-related fear-avoidance (FA) of activities of daily living, and functional disability. The Fear Avoidance Components Scale (FACS) is a patient-reported outcome (PRO) measure, which was designed to evaluate cognitive, emotional, and behavioural dimensions of FA. Objective: The study aims were to translate the English version of the FACS into Simplified Chinese and then to examine its psychometric properties. Methods: The translation and cross-cultural adaptation of the FACS from English to Chinese was performed with standard methodology. A group of 330 subjects with chronic musculoskeletal pain completed the FACS-Chi and additional FA-related PRO measures. The FACS-Chi was then completed a second time, 1 week later. Results: The FACS-Chi showed excellent internal consistency (Cronbach's alpha = 0.920) and test-retest reliability (ICC = 0.918). A confirmatory factor analysis of the 2-factor model determined in the original English version of FACS revealed an acceptable fit. Strong correlations were found between FACS-Chi scores and other PRO measures of perceived level of disability, pain catastrophizing, and pain-related anxiety (p < 0.001 for all analyses). Conclusions: The FACS-Chi demonstrated good psychometric properties, including excellent test-retest reliability and internal consistency and satisfactory construct validity. The FACS-Chi may be a useful measure of pain-related FA in Chinese-speaking patients with chronic musculoskeletal pain.

Aims: The aim of this investigation was to assess bleaching sensitivity following bleaching using either 38% H₂O₂ only or 38% H₂O₂ followed by ozone application. Methods: In this randomized controlled clinical investigation, 80 participants (40 females and 40 males) were randomly assigned to two groups (n = 40 each; 20 females and 20 males). The upper anterior teeth were bleached by 38% H₂O₂ for 20 min followed by ozone application for 60 s (healOzone X4, KaVo Dental, Biberach, Germany) in Group 1 (test group). Meanwhile, the bleaching protocol in Group 2 (controls) included the application of just 38% H₂O₂ for 20 min. Tooth sensitivity before and after bleaching was reported by the participants using a visual analog scale (VAS) from 0 to 10. Mann-Whitney U test, Wilcoxon signed-rank test, and regression analysis were used to analyze the data. Significant statistical outcomes were identified at p < 0.05. Results: Bleaching sensitivity was reported following both tested bleaching protocols (p < 0.001). However, less bleaching sensitivity was reported when ozone was applied for 60 s after bleaching with 38% H₂O₂ (p < 0.001). Female participants reported more bleaching sensitivity regardless the applied bleaching protocol (p < 0.05). Conclusions: Bleaching protocols with 38% hydrogen peroxide were associated with less bleaching sensitivity when followed by ozone application on the teeth.

Background: Several adjuvant drugs have been tried to prolong spinal anesthesia block. Currently, dexamethasone appears to be effective in extending the duration of sensory block and enhancing analgesia during surgery. It is unclear, however, whether administering dexamethasone at a dose of 8 mg offers any advantages over administering it at a dose of 4 mg. Objective: To compare the effect of adding 4 and 8 mg dexamethasone to intrathecal bupivacaine on perioperative analgesia among adult orthopedic patients at Sodo Christian Hospital from June 1 to October 31, 2021. Methodology: A total of 178 adult patients undergoing elective orthopedic surgery were randomly assigned to one of the two groups through a prospective cohort research design. A systematic random sampling method was used. For analysis, data were imported into EpiData v.4.6 and exported to SPSS v.25. Levene's test was used to verify homogeneity of variance, whereas the Shapiro-Wilk test was used to assess data distribution. The Mann-Whitney test and the independent sample t-test were employed to compare numerical variables between study groups. Category variables were determined using the chi-square test. p values were deemed statistically significant if they were less than 0.05. Result: Between groups, the perioperative and demographic features were similar. The mean durations of sensory block (347.42 ± 91.06 versus 341.46 ± 68.84), motor block (308.36 ± 80.91 versus 310.84 ± 75.50), and overall analgesia (421.51 ± 121.62 versus 412.40 ± 107.0) minutes did not show a statistically significant difference between the groups. In addition, there was no significant difference (p > 0.05) in postoperative analgesic use, initial analgesia rescue time, or pain severity, as measured by the Numerical Rating Scale (NRS). The addition of dexamethasone did not result in any issues, nor was there a statistically significant difference in the onset time between the two groups. Conclusion: Dexamethasone at a dose of 4 mg extends the duration of sensory, motor, and overall analgesia in a manner similar to that of 8 mg dexamethasone with comparable durations for both the initial analgesic request and overall analgesic use.

The incidence of peripheral nerve injury (PNI) in China is continuously increasing. With an inability to function due to sensory and motor abnormalities, patients with PNI suffer from neuropathic pain and subsequent lesions. Presently, effective treatments for PNI are limited. To determine the role of neuroprotectin D1 (NPD1) in PNI, a sciatic nerve crush injury model was developed to investigate the impact of NPD1 on sensory and motor function recovery following nerve injury. The results demonstrated that NPD1 administered at different time points might reduce mechanical allodynia and thermal hyperalgesia caused by PNI, and its analgesic effect was not tolerated. Immunohistochemistry analyses revealed that administering NPD1 to PNI mice decreased the spinal microglia and astrocyte activation and decreased the inflammatory factor expression in the spinal dorsal horn. Furthermore, NPD1 can inhibit the invasion of IBA-1⁺ macrophages in dorsal root ganglions generated by nerve injury. Meanwhile, it can help rehabilitate motor and neuromuscular functions following PNI. The results indicate that NPD1 may be involved in the sensory and motor function recovery following PNI.

Background: Current evidence indicates that some phenotypic characteristics, such as eye or hair color, might be associated with the experience of pain. We, therefore, compared the anesthetic success rate of inferior alveolar nerve block (IANB) and postoperative pain scores between light eyes and dark eyes in female patients who experienced symptomatic irreversible pulpitis (SIP) in a mandibular molar. Methods: This prospective, parallel-group, observational study was registered with ClinicalTrials.gov (NCT06206304). A total of 110 adult female patients who experienced moderate or severe pain with SIP participated in this study. All patients received IANB with 4% articaine with 1:100.000 epinephrine. Endodontic access cavity preparation was initiated after confirmation of IANB. Pain during treatment was recorded by using a Visual Analog Scale. Anesthetic success was recorded as "none" or "mild" pain. Root canal treatment was performed, with standardized protocols. Postoperative pain scores were also recorded at 24, 48, and 72 h and 7 days after treatment. Statistical analyses of the data were performed using the independent t-test, repeated measures ANOVA test, and Pearson's chi-square test. The statistical significance level was set at 0.05. Results: No significant differences were found in the success rate of IANB and postoperative pain scores between light- and dark-eyed patients at any time point (p > 0.05). The success rate of IANB was 72.73% and 67.27% for light- and dark-eyed patients, respectively. Conclusion: Pain scores decreased significantly after RCT in both groups on all days (p < 0.05). No significant differences were found in the success rate of IANB and postop pain scores between light- and dark-eyed female patients who experienced SIP in a mandibular molar. Trial Registration: ClinicalTrials.gov identifier: NCT06206304.

Background: Cancer-related pain is a pervasive symptom affecting the quality of life in patients with malignant tumors. For those with refractory pain, palliative sedation combined with pain management is recommended. Dexmedetomidine (DEX), known for its unique "awake sedation" effect, remains relatively unexplored when used in conjunction with patient-controlled analgesia (PCA) for terminal-stage cancer patients. This study aimed to assess the safety and efficacy of DEX for palliative sedation with PCA in patients experiencing refractory pain. Methods: A retrospective analysis was conducted on terminal-stage cancer patients who received DEX for palliative sedation combined with PCA in a hospice ward between January 2020 and June 2023. Data collection included general patient information, laboratory tests, rating scales, pain and analgesia conditions, sedation details, palliative sedative effects, and changes in vital signs before and after sedation. Results: Nine patients with terminal-stage cancer received DEX palliative sedation at doses ranging from 0.2 to 1.0 μg/kg·h combined with PCA for refractory pain. After 1 h of sedation and at the maximum sedation dose, the Richmond Agitation-Sedation Scale scores significantly decreased (all p < 0.001). While heart rate, blood oxygen saturation, and respiratory rate remained stable, systolic blood pressure and diastolic blood pressure after 1 h of sedation were significantly lower than presedation levels (p = 0.040 and p = 0.044, respectively). Conclusion: DEX emerges as a promising option for palliative sedation in terminal-stage cancer patients. When used in conjunction with PCA, DEX has been shown to effectively, safely, and stably control refractory pain without inducing adverse effects such as respiratory/circulatory depression.

Objective: This study aims to investigate the impact of postgraduate education on the comprehension of Temporomandibular Disorders (TMDs) among dental professionals. Methods: A cross-sectional observational study was conducted, involving 348 dental professionals, including students and practicing dentists, categorized based on their educational background into two groups: bachelor's degree or lower (Group B) and master's degree or higher (Group M). Questionnaires were utilized to assess attitudes and knowledge across four TMDs-related domains. Statistical analysis was performed to compare responses between groups and identify differences in TMDs comprehension. Results: Among the 348 respondents, who participated in the study, 183 were students and 165 were practicing dentists, yielding a response rate of 79% (348/440). In the dentist group, 11 statements across every TMDs-related domain exhibited statistically significant differences in responses between Group B and Group M (p < 0.05). Only 2 responses from Group M conflicted with the standard answers, whereas Group B had 9 conflicting responses. In the student group, 11 statements also showed statistically significant differences between Group B and Group M (p < 0.05). Group M had no conflicting responses with the standard answers, while Group B had 7 conflicting responses. Conclusions: Postgraduate education deepened dental professionals' understanding of TMDs. Students improved more in the domains of "diagnosis" and "treatment and prognosis," whereas practicing dentists enhanced more in the "etiology" domain. To further advance postgraduate education, there is a need for more systematic course designs for TMDs, emphasizing the enhancement of knowledge related to examination methods and treatment options.

Although previous studies suggest that Piezo2 regulates chronic pain in the orofacial area, few studies have reported the direct evidence of Piezo2's involvement in inflammatory and neuropathic pain in the orofacial region. In this study, we used male Sprague Dawley rats to investigate the role of the Piezo2 pathway in the development of inflammatory and neuropathic pain. The present study used interleukin (IL)-1β-induced pronociception as an inflammatory pain model. Subcutaneous injection of IL-1β produced significant mechanical allodynia and thermal hyperalgesia. Subcutaneous injection of a Piezo2 inhibitor significantly blocked mechanical allodynia and thermal hyperalgesia induced by subcutaneously injected IL-1β. Furthermore, the present study also used a neuropathic pain model caused by the misplacement of a dental implant, leading to notable mechanical allodynia as a consequence of inferior alveolar nerve injury. Western blot analysis revealed increased levels of Piezo2 in the trigeminal ganglion and the trigeminal subnucleus caudalis after inferior alveolar nerve injury. Furthermore, subcutaneous and intracisternal injections of a Piezo2 inhibitor blocked neuropathic mechanical allodynia. These results suggest that the Piezo2 pathway plays a critical role in the development of inflammatory and neuropathic pain in the orofacial area. Therefore, blocking the Piezo2 pathway could be the foundation for developing new therapeutic strategies to treat orofacial pain conditions.

Background: Trigeminal postherpetic neuralgia (TPHN) is a severe chronic pain that can lead to various socioeconomic consequences. Therefore, it is necessary to explore optimal treatment options for acute/subacute herpes zoster (HZ)-related trigeminal neuralgia and prevent the further development of TPHN. High-voltage, long-duration pulsed radiofrequency (HL-PRF) of the Gasserian ganglion is a new surgical intervention used to treat PHN. A ganglion block has been reported to possess anti-inflammatory effects and potential analgesic benefits. Methods: We included 83 patients with HZ-related acute/subacute trigeminal neuralgia admitted from January 1, 2021, to June 1, 2023, and received Gasserian ganglion HL-PRF combined with block. A 6-month follow-up was conducted, including Numerical Rating Scale (NRS) scores, Pittsburgh Sleep Quality Index (PSQI), the incidence of TPHN, the dosage of anticonvulsants and analgesics, efficacy, and adverse events. Results: All patients showed a significant decrease in postoperative NRS scores (p < 0.05). The NRS scores of the acute HZ group were consistently lower than those of the subacute HZ group at different time points (p < 0.01). The overall incidence of TPHN from the onset of HZ to 12 weeks is 21.68%. The incidence of TPHN in the acute phase group was 12.77%, significantly lower than the 33.33% in the subacute phase group (p=0.024). The effective rate was 74.7% in all patients, at 3 months after the treatment. The effective rate was 82.98% in the acute phase group and 63.89% in the subacute phase group, showing a statistically significant difference (p=0.047). The PSQI score of the acute group was consistently lower than that of the subacute group (p < 0.01). The dosage of analgesics and anticonvulsants used in the acute HZ group was lower than that in the subacute group (p < 0.01). All patients did not experience serious adverse reactions. Conclusions: Gasserian ganglion HL-PRF combined with block can be an effective and safe technique to relieve the pain of acute/subacute zoster-related trigeminal neuralgia and prevent the incidence of TPHN.